Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.55 |
| ▸ | PPARG | P37231 | 8/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5365685 | 0.90 | PPARA (0.55) | PPARAPPARGCYP1A2CYP3A4MEN1 | |
| SCHEMBL5352421 | 0.86 | PPARA (0.48) | PPARAPPARGCYP1A2CYP3A4ABCB11 | |
| SCHEMBL5324762 | 0.82 | PPARG (0.55) | PPARAPPARGPPARDADRB3 | |
| SCHEMBL5324776 | 0.81 | PPARA (0.54) | PPARAPPARGCYP1A2CYP3A4MEN1 | |
| SCHEMBL5361601 | 0.78 | PPARA (0.50) | PPARAPPARGMAPTTSHRPPARD | |
| SCHEMBL9119394 | 0.78 | MMP8 (0.56) | PPARAPPARGMEN1KMT2APPARD | |
| SCHEMBL14392329 | 0.78 | MMP8 (0.56) | PPARAPPARGMEN1KMT2APPARD | |
| SCHEMBL6575581 | 0.78 | PPARG (0.45) | PPARAPPARGPPARD | |
| SCHEMBL5375683 | 0.78 | PPARG (0.45) | PPARAPPARGPPARD | |
| SCHEMBL10203542 | 0.77 | PPARG (0.68) | PPARAPPARGCYP1A2CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-05-25 | — | — | US | disclosed |
| EP-1517882-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000789-A9 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004000789-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | PPARA 2/4885PPARG 1/4885CYP1A2 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.